Garial Immunotherapeutics

Garial Immunotherapeutics is a clinical-stage biotechnology company focused on developing novel therapies for autoimmune and inflammatory diseases, with a primary emphasis on celiac disease. The company's lead candidate, GI-101, is a monoclonal antibody designed to target and neutralize Interleukin-15 (IL-15), a key cytokine involved in the pathogenesis of celiac disease and other gastrointestinal disorders. By blocking IL-15 signaling, Garial aims to prevent the immune-mediated damage to the small intestine that occurs in patients with celiac disease upon gluten exposure. The company is currently advancing its pipeline through early-stage clinical trials to establish safety and proof-of-concept in human subjects.